Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR, with inflammatory bowel disease

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Attinkara, Ragam ^a   Mwinyi, Jessica ^a   Truninger, Kaspar ^b,d   Regula, Jaroslaw ^c   Gaj, Pawel ^c   Rogler, Gerhard ^a   Kullak Ublick, Gerd A ^a   Eloranta, Jyrki J ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d Regional Hospital   (Switzerland)

Author keywords

Bile acid homeostasis; Crohns disease; Farnesoid X receptor; Inflammatory bowel disease; Single nucleotide polymorphisms; Ulcerative colitis

Indexed keywords

CELL RECEPTOR; FARNESOID X RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR;

ADULT; AGED; ARTICLE; CROHN DISEASE; ENTERITIS; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HAPLOTYPE; HUMAN; MALE; MIDDLE AGED; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; ULCERATIVE COLITIS;

ADULT; AGED; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; INFLAMMATORY BOWEL DISEASES; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RISK FACTORS;

EID: 84865344897     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-461     Document Type: Article

References (60)

1. Inflammatory bowel disease. Kaser A, Zeissig S, Blumberg RS, Annu Rev Immunol 2010 28 573 621 10.1146/annurev-immunol-030409-101225 20192811
2. Disease concordance, zygosity, and NOD2/CARD15 status: follow-up of a population-based cohort of Danish twins with inflammatory bowel disease. Jess T, Riis L, Jespersgaard C, Hougs L, Andersen PS, Orholm MK, Binder V, Munkholm P, Am J Gastroenterol 2005 100 2486 2492 10.1111/j.1572-0241.2005.00224.x 16279904
3. Nuclear receptors and lipid physiology: opening the X-files. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ, Science 2001 294 1866 1870 10.1126/science.294.5548.1866 11729302
4. The nuclear receptor superfamily: the second decade. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, et al. Cell 1995 83 835 839 10.1016/0092-8674(95)90199-X 8521507
5. Differential recognition of target genes by nuclear receptor monomers, dimers, and heterodimers. Glass CK, Endocr Rev 1994 15 391 407 8076589
6. Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Eloranta JJ, Kullak-Ublick GA, Arch Biochem Biophys 2005 433 397 412 10.1016/j.abb.2004.09.019 15581596
7. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Wang H, Chen J, Hollister K, Sowers LC, Forman BM, Mol Cell 1999 3 543 553 10360171
8. Bile acids: natural ligands for an orphan nuclear receptor. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, et al. Science 1999 284 1365 1368 10.1126/science.284.5418.1365 10334993
9. Identification of a nuclear receptor for bile acids. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B, Science 1999 284 1362 1365 10.1126/science.284.5418.1362 10334992
10. Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. Huber RM, Murphy K, Miao B, Link JR, Cunningham MR, Rupar MJ, Gunyuzlu PL, Haws TF, Kassam A, Powell F, et al. Gene 2002 290 35 43 10.1016/S0378-1119(02)00557-7 12062799
11. Syndecan-1 expression is regulated in an isoform-specific manner by the farnesoid-X receptor. Anisfeld AM, Kast-Woelbern HR, Meyer ME, Jones SA, Zhang Y, Williams KJ, Willson T, Edwards PA, J Biol Chem 2003 278 20420 20428 10.1074/jbc.M302505200 12660231
12. Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. Laffitte BA, Kast HR, Nguyen CM, Zavacki AM, Moore DD, Edwards PA, J Biol Chem 2000 275 10638 10647 10.1074/jbc.275.14. 10638 10744760
13. The role of FXR in disorders of bile acid homeostasis. Eloranta JJ, Kullak-Ublick GA, Physiology (Bethesda) 2008 23 286 295 10.1152/physiol.00020. 2008
14. FXR regulates organic solute transporters alpha and beta in the adrenal gland, kidney, and intestine. Lee H, Zhang Y, Lee FY, Nelson SF, Gonzalez FJ, Edwards PA, J Lipid Res 2006 47 201 214 16251721
15. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes. Landrier JF, Eloranta JJ, Vavricka SR, Kullak-Ublick GA, Am J Physiol Gastrointest Liver Physiol 2006 290 476 G485 10.1152/ajpgi.00430.2005 16269519
16. Farnesoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump. Plass JR, Mol O, Heegsma J, Geuken M, Faber KN, Jansen PL, Muller M, Hepatology 2002 35 589 596 10.1053/jhep.2002.31724 11870371
17. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. Ananthanarayanan M, Balasubramanian N, Makishima M, Mangelsdorf DJ, Suchy FJ, J Biol Chem 2001 276 28857 28865 10.1074/jbc.M011610200 11387316
18. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. Schuetz EG, Strom S, Yasuda K, Lecureur V, Assem M, Brimer C, Lamba J, Kim RB, Ramachandran V, Komoroski BJ, et al. J Biol Chem 2001 276 39411 39418 10.1074/jbc.M106340200 11509573
19. Bile acid-induced negative feedback regulation of the human ileal bile acid transporter. Neimark E, Chen F, Li X, Shneider BL, Hepatology 2004 40 149 156 15239098
20. Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver. Zollner G, Wagner M, Fickert P, Geier A, Fuchsbichler A, Silbert D, Gumhold J, Zatloukal K, Kaser A, Tilg H, et al. Am J Physiol Gastrointest Liver Physiol 2005 289 798 G805 10.1152/ajpgi.00319.2004 16002565
21. The human Na+taurocholate cotransporting polypeptide gene is activated by glucocorticoid receptor and peroxisome proliferator-activated receptor-gamma coactivator-1alpha, and suppressed by bile acids via a small heterodimer partner-dependent mechanism. Eloranta JJ, Jung D, Kullak-Ublick GA, Mol Endocrinol 2006 20 65 79 16123152
22. Farnesoid X receptor responds to bile acids and represses cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. Chiang JY, Kimmel R, Weinberger C, Stroup D, J Biol Chem 2000 275 10918 10924 10.1074/jbc.275.15.10918 10753890
23. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, Galardi C, Wilson JG, Lewis MC, Roth ME, et al. Mol Cell 2000 6 517 526 10.1016/S1097-2765(00)00051-4 11030332
24. FXR activation inhibits inflammation and preserves the intestinal barrier in IBD. Wildenberg ME, van den Brink GR, Gut 2011 60 432 433 10.1136/gut.2010.233304 21270116
25. The bile acid receptor FXR is a modulator of intestinal innate immunity. Vavassori P, Mencarelli A, Renga B, Distrutti E, Fiorucci S, J Immunol 2009 183 6251 6261 10.4049/jimmunol.0803978 19864602
26. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, Downes M, Yu RT, Shelton JM, Richardson JA, Repa JJ, et al. Proc Natl Acad Sci U S A 2006 103 3920 3925 10.1073/pnas.0509592103 16473946
27. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W, Murzilli S, Klomp LW, Siersema PD, Schipper ME, Danese S, et al. Gut 2011 60 463 472 10.1136/gut.2010.212159 21242261
28. Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-[kappa]B signaling in the intestine. Biochimica et Biophysica Acta (BBA). Gadaleta RM, Oldenburg B, Willemsen ECL, Spit M, Murzilli S, Salvatore L, Klomp LWJ, Siersema PD, van Erpecum KJ, van Mil SWC, Molecular Basis of Disease 2011 1812 851 858 10.1016/j.bbadis.2011.04.005
29. Farnesoid X receptor protects human and murine gastric epithelial cells against inflammation-induced damage. Lian F, Xing X, Yuan G, Schafer C, Rauser S, Walch A, Rocken C, Ebeling M, Wright MB, Schmid RM, et al. Biochem J 2011 438 315 323 10.1042/BJ20102096 21619550
30. Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans. Kovacs P, Kress R, Rocha J, Kurtz U, Miquel JF, Nervi F, Méndez-Sánchez N, Uribe M, Bock HH, Schirin-Sokhan R, et al. J Hepatol 2008 48 116 124 10.1016/j.jhep.2007.07.027 17931734
31. Genetic factors in the pathogenesis of cholangiocarcinoma. Wadsworth CA, Dixon PH, Wong JH, Chapman MH, McKay SC, Sharif A, Spalding DR, Pereira SP, Thomas HC, Taylor-Robinson SD, et al. Dig Dis 2011 29 93 97 10.1159/000324688 21691113
32. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Van Mil SW, Milona A, Dixon PH, Mullenbach R, Geenes VL, Chambers J, Shevchuk V, Moore GE, Lammert F, Glantz AG, et al. Gastroenterology 2007 133 507 516 10.1053/j.gastro.2007.05.015 17681172
33. A novel heterozygous NRIH4 termination codon mutation in idiopathic infantile cholestasis. Chen X-Q, Wang L-L, Shan Q-W, Tang Q, Deng Y-N, Lian S-J, Yun X, World Journal of Pediatrics 2012 8 67 71 10.1007/s12519-011-0299-z 21633855
34. Genetics of inflammatory bowel disease: clues to pathogenesis. Zhang H, Massey D, Tremelling M, Parkes M, Br Med Bull 2008 87 17 30 10.1093/bmb/ldn031 18753178
35. Genome-wide meta-analysis increases to 71 the number of confirmed Crohns disease susceptibility loci. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, et al. Nat Genet 2010 42 1118 1125 10.1038/ng.717 21102463
36. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohns disease. Hugot J-P, Chamaillard M, Zouali H, Lesage S, Cezard J-P, Belaiche J, Almer S, Tysk C, OMorain CA, Gassull M, et al. Nature 2001 411 599 603 10.1038/35079107 11385576
37. A frameshift mutation in NOD2 associated with susceptibility to Crohns disease. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, et al. Nature 2001 411 603 606 10.1038/35079114 11385577
38. An induced proximity model for NF-kappa B activation in the Nod1/RICK and RIP signaling pathways. Inohara N, Koseki T, Lin J, del Peso L, Lucas PC, Chen FF, Ogura Y, Nunez G, J Biol Chem 2000 275 27823 27831 10880512
39. Human Nod1 confers responsiveness to bacterial lipopolysaccharides. Inohara N, Ogura Y, Chen FF, Muto A, Nunez G, J Biol Chem 2001 276 2551 2554 10.1074/jbc.M009728200 11058605
40. Polymorphisms of the TNF gene and the TNF receptor superfamily member 1B gene are associated with susceptibility to ulcerative colitis and Crohns disease, respectively. Sashio H, Tamura K, Ito R, Yamamoto Y, Bamba H, Kosaka T, Fukui S, Sawada K, Fukuda Y, Satomi M, et al. Immunogenetics 2002 53 1020 1027 10.1007/s00251-001-0423-7 11904678
41. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohns disease. Fisher SA, Tremelling M, Anderson CA, Gwilliam R, Bumpstead S, Prescott NJ, Nimmo ER, Massey D, Berzuini C, Johnson C, et al. Nat Genet 2008 40 710 712 10.1038/ng.145 18438406
42. Association between Toll-like receptor 4 and inflammatory bowel disease. Oostenbrug LE, Drenth JP, de Jong DJ, Nolte IM, Oosterom E, van Dullemen HM, van der Linde K, te Meerman GJ, van der Steege G, Kleibeuker JH, et al. Inflamm Bowel Dis 2005 11 567 575 15905704
43. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohns disease and ulcerative colitis. Franchimont D, Vermeire S, El Housni H, Pierik M, Van Steen K, Gustot T, Quertinmont E, Abramowicz M, Van Gossum A, Deviere J, et al. Gut 2004 53 987 992 10.1136/gut.2003.030205 15194649
44. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Wellcome Trust Case Control Consortium, Nature 2007 447 661 678 10.1038/nature05911 17554300
45. Replication of signals from recent studies of Crohns disease identifies previously unknown disease loci for ulcerative colitis. Franke A, Balschun T, Karlsen TH, Hedderich J, May S, Lu T, Schuldt D, Nikolaus S, Rosenstiel P, Krawczak M, et al. Nat Genet 2008 40 713 715 10.1038/ng.148 18438405
46. Linkage to peroxisome proliferator-activated receptor-[gamma] in SAMP1/YitFc mice and in human Crohns disease. Sugawara K, Olson TS, Moskaluk CA, Stevens BK, Hoang S, Kozaiwa K, Cominelli F, Ley KF, McDuffie M, Gastroenterology 2005 128 351 360 10.1053/j.gastro.2004.11.001 15685547
47. Evidence for association of OCTN genes and IBD5 with ulcerative colitis. Waller S, Tremelling M, Bredin F, Godfrey L, Howson J, Parkes M, Gut 2006 55 809 814 10.1136/gut.2005.084574 16361305
48. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Schwab M, Schaeffeler E, Marx C, Fromm MF, Kaskas B, Metzler J, Stange E, Herfarth H, Schoelmerich J, Gregor M, et al. Gastroenterology 2003 124 26 33 10.1053/gast.2003.50010 12512026
49. MDR1 Ala893 Polymorphism Is Associated with Inflammatory Bowel Disease. Brant SR, Panhuysen CIM, Nicolae D, Reddy DM, Bonen DK, Karaliukas R, Zhang L, Swanson E, Datta LW, Moran T, et al. Am J Hum Genet 2003 73 1282 1292 10.1086/379927 14610718
50. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Peltekova VD, Wintle RF, Rubin LA, Amos CI, Huang Q, Gu X, Newman B, Van Oene M, Cescon D, Greenberg G, et al. Nat Genet 2004 36 471 475 10.1038/ng1339 15107849
51. Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans. Kovacs P, Kress R, Rocha J, Kurtz U, Miquel JF, Nervi F, Mendez-Sanchez N, Uribe M, Bock HH, Schirin-Sokhan R, et al. J Hepatol 2008 48 116 124 10.1016/j.jhep.2007.07.027 17931734
52. Genetic variations in regulatory pathways of fatty acid and glucose metabolism are associated with obesity phenotypes: a population-based cohort study. van den Berg SW, Dolle ME, Imholz S, van der AD, van t Slot R, Wijmenga C, Verschuren WM, Strien C, Siezen CL, Hoebee B, et al. Int J Obes (Lond) 2009 33 1143 1152 10.1038/ijo.2009.152
53. Hepatobiliary disorders in inflammatory bowel disease. Christophi C, Hughes ER, Surg Gynecol Obstet 1985 160 187 193 3881836
54. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Navaneethan U, Shen B, Inflamm Bowel Dis 2010 16 1598 1619 10.1002/ibd.21219 20198712
55. A Common Polymorphism in the Bile Acid Receptor Farnesoid X Receptor Is Associated with Decreased Hepatic Target Gene Expression. Marzolini C, Tirona RG, Gervasini G, Poonkuzhali B, Assem M, Lee W, Leake BF, Schuetz JD, Schuetz EG, Kim RB, Mol Endocrinol 2007 21 1769 1780 10.1210/me.2007-0025 17519356
56. Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease. Nijmeijer RM, Gadaleta RM, van Mil SW, van Bodegraven AA, Crusius JB, Dijkstra G, Hommes DW, de Jong DJ, Stokkers PC, Verspaget HW, et al. PLoS One 2011 6 23745 10.1371/journal.pone.0023745 21887309
57. Nuclear Receptors as New Perspective for the Management of Liver Diseases. Trauner M, Halilbasic E, Gastroenterology 2011 140 1120 1125 e1112 10.1053/j.gastro.2011.02.044 21334334
58. Cohort profile: the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). Pittet V, Juillerat P, Mottet C, Felley C, Ballabeni P, Burnand B, Michetti P, Vader JP, Int J Epidemiol 2009 38 922 931 10.1093/ije/dyn180 18782896
59. A powerful strategy to account for multiple testing in the context of haplotype analysis. Becker T, Knapp M, Am J Hum Genet 2004 75 561 570 10.1086/424390 15290652
60. Haplotype interaction analysis of unlinked regions. Becker T, Schumacher J, Cichon S, Baur MP, Knapp M, Genet Epidemiol 2005 29 313 322 10.1002/gepi.20096 16240441